Mathews P. George

Mathews is a graduate of National University of Juridical Sciences, Kolkata. His interest in intellectual property was kindled when he bagged the second position in his second year of Law School (in the prestigious Nani Palkhiwala Essay Competition on Intellectual Property). His stint as a student of Prof. Shamnad Basheer further accentuated his interest in intellectual property. Winner of almost a dozen essay competitions in his Law School days, he was involved in various research and policy initiatives relating to intellectual property. Mathews is, currently, based out of Munich, Germany. He had earlier done his LLM in 'IP and Competition Law' from Munich Intellectual Property Law Centre (jointly run by Max Plank Institute for Innovation and Competition, University of Augsburg, Technical University of Munich and George Washington University, Washington).



  After the Bayh Dole Conference last year and the provocative discussions that it engendered, the NUJS IP Chair is collaborating this year with the Max Planck Institute for Intellectual Property, Competition and Tax Law. A two-day Indo-European dialogue on “Innovation, Creativity and IP Policy”, will be held at NUJS on 19th and 20th November, 2010. The Conference is sponsored by Microsoft India (chief sponsor), K&S Partners and Altacit Global. The Workshop has lined up interesting speakers to take on…

Read More »

An Earnest call for responsible reporting

The Hindustan Times (HT), quoting the joint report issued by the World Health Organisation, UNAIDS, and UNICEF, reports that over one million HIV/AIDS patients in India do not have access to anti-retroviral (ARV) treatment. India is ranked third, after South Africa and Kenya, in scaling up access towards ARV treatment. An estimated 3,20,074 patients received ARV therapy in India till the end of last year as compared to 2,34,581 patients in the previous year. According to the report, between 1.1…

Read More »

Local pharma in patent rush

The DNA news report titled “Pot-kettle? Local pharma in patent rush” criticises domestic pharma companies such as Cipla, Natco and Wockhardt which file oppositions against trivial patenting and simultaneously file patent claims for molecular tweaks. It quotes Amit Sengupta, general secretary of All India Peoples Science Network on its argument that Indian pharma firms have become aggressive on claiming patents. The trend is set to rise in future. The domestic market is expected to be worth $20 billion in five…

Read More »